Portfolio Alerts Watch List Cart

Healthcare

Refine Search


Product Compare (0)
A
Amrutanjan Health Care Ltd
Score 68/100• Decent
Amrutanjan Health Care Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
Company’s Health86/100
Valuation 20/100 · PB 6.2085
Technical Avoid
1M -8.647% 6M 4.802% 1Y -7.853%
Confidence100%
Low leverage (D/E)No promoter pledge
#106
View details ➜
A
Alembic Pharmaceuticals Ltd
Score 68/100• Decent
Alembic Pharmaceuticals shows potential for growth but faces challenges in profitability and market competition.
Company’s Health81/100
Valuation 40/100 · PB 3.4758
Technical Avoid
1M -4.099% 6M 8.412% 1Y -20.194%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#107
View details ➜
A
Akums Drugs and Pharmaceuticals Ltd
Score 68/100• Decent
Akums Drugs and Pharmaceuticals Ltd shows potential for growth, but faces challenges in profitability and market competition.
Company’s Health79/100
Valuation 60/100 · PB 2.3161
Technical Avoid
1M -1.278% 6M -2.871% 1Y -47.371%
Confidence100%
Low leverage (D/E)No promoter pledge
#108
View details ➜
G
GlaxoSmithKline Pharmaceuticals Ltd
Score 68/100• Decent
GlaxoSmithKline Pharmaceuticals Ltd shows decent fundamentals but faces challenges in profitability and market sentiment. It is a stable player in a growing sector, but caution is advised due to valuation concerns and execution risks.
Company’s Health84/100
Valuation 20/100 · PB 23.7504
Technical Avoid
1M -0.765% 6M -4.951% 1Y 1.21%
Confidence100%
Low leverage (D/E)No promoter pledge
#109
View details ➜
G
Gland Pharma Ltd
Score 68/100• Decent
Gland Pharma shows potential for growth but faces challenges in profitability and market competition.
Company’s Health86/100
Valuation 40/100 · PB 3.4866
Technical Avoid
1M -5.047% 6M 35.771% 1Y 17.374%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#110
View details ➜
F
Fischer Medical Ventures Ltd
Score 68/100• Decent
Fischer Medical Ventures Ltd shows potential but faces several challenges that may hinder growth and profitability.
Company’s Health73/100
Valuation 20/100 · PB 17.9567
Technical Avoid
1M -16.356% 6M 12.983% 1Y 42.639%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#111
View details ➜
F
F D C Ltd
Score 68/100• Decent
F D C Ltd shows potential for growth in a stable sector, but faces challenges in profitability and valuation metrics.
Company’s Health86/100
Valuation 40/100 · PB 3.1144
Technical Avoid
1M -5.86% 6M 2.671% 1Y -22.756%
Confidence100%
Low leverage (D/E)No promoter pledge
#112
View details ➜
D
Dr. Agarwal's Health Care Ltd
Score 68/100• Decent
Dr. Agarwal's Health Care Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should proceed with caution.
Company’s Health65/100
Valuation 20/100 · PB 8.5717
Technical Momentum
1M 19.972% 6M 27.29% 1Y 30.063%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#113
View details ➜
C
Concord Drugs Ltd
Score 68/100• Decent
Concord Drugs Ltd shows potential but faces significant challenges in growth and profitability metrics.
Company’s Health71/100
Valuation 80/100 · PB 1.9056
Technical Avoid
1M -5.016% 6M 109.881% 1Y 75.202%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#114
View details ➜
C
Caplin Point Laboratories Ltd
Score 68/100• Decent
Caplin Point Laboratories Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health100/100
Valuation 20/100 · PB 5.318
Technical Avoid
1M -12.896% 6M 4.871% 1Y 5.021%
Confidence100%
Low leverage (D/E)No promoter pledge
#115
View details ➜
B
Brooks Laboratories Ltd
Score 68/100• Decent
Brooks Laboratories Ltd shows potential in a growing sector, but faces challenges in growth consistency and profitability metrics.
Company’s Health55/100
Valuation 40/100 · PB 3.6984
Technical Avoid
1M -21.184% 6M -12.265% 1Y -16.204%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#116
View details ➜
B
Blue Jet Healthcare Ltd
Score 68/100• Decent
Blue Jet Healthcare Ltd shows potential for growth but faces significant challenges in profitability and execution risks.
Company’s Health100/100
Valuation 20/100 · PB 10.1321
Technical Avoid
1M -8.021% 6M -10.13% 1Y 27.23%
Confidence100%
Low leverage (D/E)No promoter pledge
#117
View details ➜
A
Anlon Healthcare Ltd
Score 68/100• Decent
Anlon Healthcare Ltd shows potential for growth, but faces challenges in valuation and execution risks.
Company’s Health70/100
Valuation 20/100 · PB 8.4103
Technical Watch
1M 15.489% 6M 38.722% 1Y 38.722%
Confidence100%
No promoter pledgeHealthy profit margins
#118
View details ➜
A
Aditya BSL Nifty Healthcare ETF
Score 68/100• Decent
The Aditya BSL Nifty Healthcare ETF shows potential for growth in a vital sector, but faces challenges in valuation and governance that investors should consider.
Company’s Health0/100
Valuation 0/100 · PB —
Technical Avoid
1M -1.655% 6M 3.336% 1Y -2.998%
Confidence80%
#119
View details ➜
A
Accretion Pharmaceuticals Ltd
Score 68/100• Decent
Accretion Pharmaceuticals Ltd shows potential but faces challenges in growth consistency and valuation metrics.
Company’s Health91/100
Valuation 40/100 · PB 4.1331
Technical Avoid
1M -9.592% 6M -31.465% 1Y -31.465%
Confidence100%
No promoter pledgeDecent revenue growth
#120
View details ➜
Showing 106 to 120 of 301 (21 Pages)